Jacques Lemmens

428 total citations
4 papers, 307 citations indexed

About

Jacques Lemmens is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy. According to data from OpenAlex, Jacques Lemmens has authored 4 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Immunology and Allergy. Recurrent topics in Jacques Lemmens's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (1 paper). Jacques Lemmens is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (1 paper). Jacques Lemmens collaborates with scholars based in . Jacques Lemmens's co-authors include David Egging, Gijs Verheijden, Wim H.A. Dokter, Ruud Ubink, Patrick H. Beusker, Miranda M.C. van der Lee, Franciscus M. H. de Groot, Ruud G. E. Coumans, Diels J. van den Dobbelsteen and C. Marco Timmers and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Molecular Pharmaceutics.

In The Last Decade

Jacques Lemmens

4 papers receiving 294 citations

Peers

Countries citing papers authored by Jacques Lemmens

Since Specialization

Citations

This map shows the geographic impact of Jacques Lemmens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Lemmens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Lemmens more than expected).

Fields of papers citing papers by Jacques Lemmens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Lemmens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Lemmens. The network helps show where Jacques Lemmens may publish in the future.

Co-authorship network of co-authors of Jacques Lemmens

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Lemmens. A scholar is included among the top collaborators of Jacques Lemmens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Lemmens. Jacques Lemmens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

#	Work	Indexed citations
1	Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985 2015 ·Molecular Pharmaceutics ·Ronald C. Elgersma, Ruud G. E. Coumans, (unknown), Wiro M. P. B. Menge, John Joosten, Henri Spijker, Franciscus M. H. de Groot, Miranda M.C. van der Lee, Ruud Ubink, Diels J. van den Dobbelsteen, David Egging, Wim H.A. Dokter, Gijs Verheijden, Jacques Lemmens, C. Marco Timmers, Patrick H. Beusker	163
2	The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers 2015 ·Molecular Cancer Therapeutics ·Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink, (unknown), (unknown), Eline M. Loosveld, (unknown), Daniëlle C.H. Jacobs, (unknown), David Egging, Diels van den Dobbelsteen, Patrick H. Beusker, (unknown), Gijs Verheijden, Jacques Lemmens, Marco Timmers, Wim H.A. Dokter	141
3	Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers 2015 ·Cancer Research ·(unknown), (unknown), Patrick G. Groothuis, Ruud Ubink, (unknown), (unknown), Eline M. Loosveld, (unknown), (unknown), David Egging, Diels van den Dobbelsteen, Patrick H. Beusker, (unknown), Gijs Verheijden, Jacques Lemmens, Marco Timmers	1
4	Abstract 4329: Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC. 2013 ·Cancer Research ·Wim H.A. Dokter, Patrick H. Beusker, Gijs Verheijden, Ruud Ubink, (unknown), Diels van den Dobbelsteen, (unknown), Jacques Lemmens, Vincent de Groot, Marco Timmers	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact